{"id":263,"date":"2025-01-08T22:00:00","date_gmt":"2025-01-08T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=263"},"modified":"2025-09-08T14:04:56","modified_gmt":"2025-09-08T14:04:56","slug":"china-bd-2025-dualitybio-and-avenzo-enters-a-1-2-billion-usd-license-for-egfr-her3-bsadc-db-1418-avzo-1418","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/263.html","title":{"rendered":"[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR\/HER3 BsADC DB-1418 (AVZO-1418)"},"content":{"rendered":"\n<p>Announced Date: 2025-01-07 (January\u00a07, 2025)<\/p>\n\n\n\n<p>Asset Name: DB-1418 (AVZO-1418)<\/p>\n\n\n\n<p>Licensor (Seller): Duality Biotherapeutics (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Avenzo Therapeutics (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: ADC (antibody drug conjugate)\u00a0, topoisomerase-1 inhibitor-based<\/p>\n\n\n\n<p>Asset Target: targeting both EGFR and HER3<\/p>\n\n\n\n<p>Potential Indication: \u00a0multiple solid tumor\u00a0<\/p>\n\n\n\n<p>Current Stage: preclinical<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: &nbsp;<\/p>\n\n\n\n<p>Avenzo will develop, manufacture and commercialize AVZO-1418\/DB-1418 globally (excluding Greater China).<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>DualityBio will receive<\/p>\n\n\n\n<p> Upfront payment of $50 million, <\/p>\n\n\n\n<p>Development, regulatory and commercial milestone payments up to approximately $1.15 billion. <\/p>\n\n\n\n<p>Tiered royalties on sales in Avenzo\u2019s territory.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/avenzotx.com\/press-releases\/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate\/\">Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR\/HER3 Antibody-Drug Conjugate | Avenzo Therapeutics (avenzotx.com)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Duality Biotherapeutics, \u6620\u6069\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-01-07 (January\u00a07, 2025) Asset Name: DB-1418 (AVZO-1418) Licensor (Seller): Duality Biotherapeutics (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR\/HER3 BsADC DB-1418 (AVZO-1418)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/263.html\"><span class=\"screen-reader-text\">[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR\/HER3 BsADC DB-1418 (AVZO-1418)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-263","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=263"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/263\/revisions"}],"predecessor-version":[{"id":264,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/263\/revisions\/264"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}